Literature DB >> 20934857

Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation--the J-RHYTHM Registry study design.

Hirotsugu Atarashi1, Hiroshi Inoue, Ken Okumura, Takeshi Yamashita, Hideki Origasa.   

Abstract

BACKGROUND: In order to prevent stroke in atrial fibrillation (AF) lower international normalized ratios (INR) (1.6-2.6) were recommended for elderly Japanese patients, but only one clinical study supported this recommendation. METHODS AND
RESULTS: The J-RHYTHM Registry is a large, contemporary, prospective observational investigation, with a 2-year follow-up, of patients with AF. Over 6000 AF patients of all types under clinical observation at approximately 150 sites in 10 geographical regions that together cover the whole of Japan will be enrolled in numbers proportional to the population densities of those areas. The primary endpoints of the study will be symptomatic stroke including transient ischemic attack, systemic thromboembolism, and major bleeding including intracranial hemorrhage requiring hospitalization. At each visit, the accumulated demographic data and INR will be examined to determine the appropriate INR for Japanese AF patients.
CONCLUSIONS: The study will offer a contemporary overview of the anticoagulation status throughout Japan, and will follow more than 6000 patients spread throughout the country for 2 years, to obtain important information, including the optimal INR for Japanese AF patients (UMIN Clinical Trials Registry UMIN000001569).
Copyright © 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20934857     DOI: 10.1016/j.jjcc.2010.09.002

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  13 in total

1.  Atrial fibrillation and flutter outcomes and risk determination (AFFORD): design and rationale.

Authors:  Tyler W Barrett; Alan B Storrow; Cathy A Jenkins; Frank E Harrell; Karen F Miller; Kelly M Moser; Stephan Russ; Dan M Roden; Dawood Darbar
Journal:  J Cardiol       Date:  2011-08-04       Impact factor: 3.159

2.  Indonesian registry on atrial fibrillation (OneAF).

Authors:  Sunu Budhi Raharjo; Agung Fabian Chandranegara; Dicky Armein Hanafy; Muhammad Yamin; Hauda El Rasyid; Ardian Rizal; Pipin Ardhianto; Dony Yugo Hermanto; Yoga Yuniadi
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

3.  Analytical Management of Patients Undergoing Oral Anticoagulant Therapy Could Have a Strong Impact on Clinical Outcomes: A Follow-up Study.

Authors:  Vincenzo De Iuliis; Sebastiano Ursi; Gianfranco Vitullo; Irma Griffo; Antonio Marino; Marika Caruso; Francesco Cipollone; Sabrina Capodifoglio; Veronica Breda; Elena Toniato; Alfonso Pennelli; Pio Conti; Stefano Martinotti
Journal:  Cardiol Ther       Date:  2017-05-19

4.  Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry.

Authors:  Eitaro Kodani; Hirotsugu Atarashi; Hiroshi Inoue; Ken Okumura; Takeshi Yamashita; Hideki Origasa
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2018-01-01

5.  Design and Rationale of the National Tunisian Registry of Atrial Fibrillation: Protocol for a Prospective, Multicenter Trial.

Authors:  Afef Ben Halima; Sana Ouali; Mohamed Sami Mourali; Sonia Chabrak; Rafik Chettaoui; Manel Ben Halima; Abdeddayem Haggui; Noureddine Larbi; Salma Krichène; Sonia Marrakchi; Slim Kacem; Rim Chrigui; Mohamed Fahmi Abbes; Hédi Baccar; Nadia Baraket; Najeh Ben Halima; Ali Ben Khalfallah; Mohamed Ben Mbarek; Soraya Ben Youssef; Essia Boughzala; Mohamed Rachid Boujnah; Habiba Drissa; Habib Gamra; Ali Gasmi; Habib Haouala; Youssef Harrath; Ines Issa; Gouider Jeridi; Salem Kachboura; Samir Kammoun; Sondes Kraiem; Faouzi Maatouk; Sami Milouchi; Wided Nasraoui; Ali Neji; Khaled Sayahi; Wissem Sdiri; Wajih Smati; Samir Tlili; Leila Abid; Salem Abdesselem; Lilia Zakhama; Abdallah Mahdhaoui; Helmi Kammoun; Skander Ben Omrane; Faouzi Addad
Journal:  JMIR Res Protoc       Date:  2018-10-15

6.  Predictive ability of creatinine clearance versus estimated glomerular filtration rate for outcomes in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry.

Authors:  Eitaro Kodani; Hiroshi Inoue; Hirotsugu Atarashi; Hirofumi Tomita; Ken Okumura; Takeshi Yamashita; Hideki Origasa
Journal:  Int J Cardiol Heart Vasc       Date:  2020-06-10

7.  Cohort profile: patient characteristics and quality-of-life measurements for newly-referred patients with atrial fibrillation-Keio interhospital Cardiovascular Studies-atrial fibrillation (KiCS-AF).

Authors:  Nobuhiro Ikemura; John A Spertus; Takehiro Kimura; Kenneth Mahaffey; Jonathan P Piccini; Taku Inohara; Ikuko Ueda; Kojiro Tanimoto; Masahiro Suzuki; Iwao Nakamura; Makoto Akaishi; Hideo Mitamura; Keiichi Fukuda; Seiji Takatsuki; Shun Kohsaka
Journal:  BMJ Open       Date:  2019-12-18       Impact factor: 2.692

8.  Rationale and design of the Chinese Atrial Fibrillation Registry Study.

Authors:  Xin Du; Changsheng Ma; Jiahui Wu; Songnan Li; Man Ning; Ribo Tang; Xueyuan Guo; Deyong Long; Ronghui Yu; Caihua Sang; Chenxi Jiang; Ting Zhang; Jianhong Pan; Xiaohui Liu; Jianzeng Dong; Gregory Y H Lip
Journal:  BMC Cardiovasc Disord       Date:  2016-06-07       Impact factor: 2.298

9.  Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J-RHYTHM Registry.

Authors:  Eitaro Kodani; Hirotsugu Atarashi; Hiroshi Inoue; Ken Okumura; Takeshi Yamashita; Toshiaki Otsuka; Hirofumi Tomita; Hideki Origasa
Journal:  J Am Heart Assoc       Date:  2016-09-12       Impact factor: 5.501

10.  A survey of reasons for continuing warfarin therapy in the era of direct oral anticoagulants in Japanese patients with atrial fibrillation: the SELECT study.

Authors:  Takanori Ikeda; Masahiro Yasaka; Makoto Kida; Miki Imura
Journal:  Patient Prefer Adherence       Date:  2018-01-17       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.